Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cullinan Management (CGEM)
NASDAQ:CGEM
Holding CGEM?
Track your performance easily
CGEM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.64 - $30.19
Previous Close$12.58
Volume223.13K
Average Volume (3M)534.08K
Market Cap
$743.98M
Enterprise Value$187.15M
Total Cash (Recent Filing)$578.08M
Total Debt (Recent Filing)$2.45M
Price to Earnings (P/E)―
Beta1.49
Next Earnings
Mar 06, 2025EPS Estimate
-$0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.88
Shares Outstanding58,227,593
10 Day Avg. Volume679,223
30 Day Avg. Volume534,084
Standard Deviation0.17
R-Squared0.00103
Alpha-0.00546
Financial Highlights & Ratios
Price to Book (P/B)1.17
Price to Sales (P/S)1525.56
Price to Cash Flow (P/CF)-5.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue374.30
Enterprise Value/Gross Profit374.30
Enterprise Value/Ebitda-1.00
Forecast
1Y Price Target
$33.00Price Target Upside168.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Cullinan Management News
PremiumCompany Announcements
Cullinan Therapeutics Announces Q3 2024 Progress and Outlook
PremiumCompany Announcements
Cullinan Management Advances SLE Treatment with FDA TrialBulls Say, Bears Say
Bulls Say
Financial PositionCullinan's cash balance as of September 30, 2024, was $639.0 million, indicating a solid financial position.
Regulatory MilestonesThe FDA cleared the IND application for CLN-978, a novel T cell engager, indicating potential progress in autoimmune disease treatment.
Treatment AdvancementsCullinan and CLN-978 are uniquely positioned to deliver several first-in-class proof-of-concept data for CD19 T-cell engagers across autoimmune diseases.
Bears Say
EarningsCullinan is decreasing its FY24 EPS estimate, indicating potential financial performance concerns.
RisksRisks include commercial, regulatory, development, manufacturing, financial/dilution, and liability challenges.
SafetyA black box warning is carried by the entire class, and complicated conversations and safety signals being more pronounced in certain indications could represent a continued impediment to JAK uptake.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CGEM FAQ
What was Cullinan Management’s price range in the past 12 months?
Cullinan Management lowest stock price was $7.64 and its highest was $30.19 in the past 12 months.
What is Cullinan Management’s market cap?
Currently, no data Available
When is Cullinan Management’s upcoming earnings report date?
Cullinan Management’s upcoming earnings report date is Mar 06, 2025 which is in 104 days.
How were Cullinan Management’s earnings last quarter?
Cullinan Management released its earnings results on Nov 07, 2024. The company reported -$0.69 earnings per share for the quarter, beating the consensus estimate of -$0.788 by $0.098.
Is Cullinan Management overvalued?
According to Wall Street analysts Cullinan Management’s price is currently Undervalued.
Does Cullinan Management pay dividends?
Cullinan Management does not currently pay dividends.
What is Cullinan Management’s EPS estimate?
Cullinan Management’s EPS estimate is -$0.79.
How many shares outstanding does Cullinan Management have?
Cullinan Management has 58,227,592 shares outstanding.
What happened to Cullinan Management’s price movement after its last earnings report?
Cullinan Management reported an EPS of -$0.69 in its last earnings report, beating expectations of -$0.788. Following the earnings report the stock price went down -5.461%.
Which hedge fund is a major shareholder of Cullinan Management?
Among the largest hedge funds holding Cullinan Management’s share is Deerfield Management Company, LP. It holds Cullinan Management’s shares valued at 55M.
---
Cullinan Management Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.00 (168.95% Upside)
$33.00 (168.95% Upside)
Hedge Fund Trend
Decreased
By 750.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 6.5%
Last 30 Days ▲ 4.0%
Last 30 Days ▲ 4.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
43.60%
12-Months-Change
Fundamentals
Return on Equity
-26.18%
Trailing 12-Months
Asset Growth
32.05%
Trailing 12-Months
Company Description
Cullinan Management
Cullinan Management Inc is a biopharmaceutical company. It is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients.
---
CGEM Stock 12 Month Forecast
Average Price Target
$33.00
▲(168.95% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Cabaletta Bio
―
Corvus Pharmaceuticals
―
Foghorn Therapeutics
―
Best Analysts Covering CGEM
1 Year
1 Year Success Rate
10/28 ratings generated profit
1 Year Average Return
+3.07%
reiterated a buy rating 14 days ago
Copying Edward White's trades and holding each position for 1 Year would result in 35.71% of your transactions generating a profit, with an average return of +3.07% per trade.
---